According to a recent report from the Japanese Ministry of Health and Welfare, the mortality
rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop ulation. In addition …

Hepatocellular carcinoma (HCC) is one of the major malignant diseases in many healthcare
systems. The growing number of new cases diagnosed each year is nearly equal to the …

Treatment for HCC depends on the stage of the tumor and of the chronic liver disease or
cirrhosis. The former dictates the chance of cure or response to therapy, whereas the latter …

Hepatocellular carcinoma (HCC) is a heterogeneous disease that develops most of the time
in the diseased liver. Early diagnosis and management are the best options for patients, so …

Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC),
mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to …

Background Prior to INASL guidelines, there were no Indian guidelines for management of
hepatocellular carcinoma (HCC) in India. The guidelines given by other societies like …

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third
leading cause of cancer death [1]. Worldwide in 2018, there were over 840,000 new cases …

Heptatocellular (HCC) is a rapidly progressive fatal malignancy often presenting at an
advanced stage at the time of initial diagnosis. Loco-regional therapies for early-stage HCC …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies
worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited …

Background: Due to the number of emerging new treatment options, the systemic treatment
of hepatocellular carcinoma (HCC) is rapidly changing. We provide here an overview of the …